Interview Frederic Triebel with PharmaTelevisionGet the Flash Player to see this video.
Published 02/2012 by email@example.com
© 2002 Immutep, S.A.
04/2012 - Immutep and Lonza Sign Agreement for Cell Line Selection, Cell Banking and Process Development of ImmuFact® IMP321
Immutep and Lonza announced today an agreement for cell line ...
02/2012 - Interview Frederic Triebel with PharmaTelevision
Get the Flash ...
01/2011 - Immutep and GlaxoSmithKline sign licence agreement for IMP731, a novel therapeutic antibody for the treatment of autoimmune diseases
Immutep S.A. announced today the execution of a licence agreement ...
09/2010 - Immutep announces final results in phase I/II chemoimmunotherapy trial in metastatic breast cancer.
Clinical research paper describes IMP321’s potency in achieving ...
05/2010 - Immutep Announces Oral Presentation at ASCO Annual Meeting of IMP321 Final Results In Phase I/II Chemoimmunotherapy Trial
Immutep S.A. announced today that the final results from its Phase ...